Nitrofurantoin and Fosfomycin

Macrobid (Nitrofurantoin): Overview

Nitrofurantoin (commonly known by its brand name Macrobid) is an antibiotic commonly used to treat urinary tract infections (UTIs). It is specifically effective in the urinary tract due to its concentration in the urine, and it works by damaging bacterial DNA.

---

Mechanism of Action:

Nitrofurantoin is reduced by bacterial enzymes into reactive intermediates that damage bacterial DNA, proteins, and cell walls, ultimately killing the bacteria.

---

Spectrum:

1. Gram-positive bacteria:

   • Effective against Enterococcus faecalis, including VRE (vancomycin-resistant enterococci)
   • Covers Staphylococcus saprophyticus, an important cause of UTIs in women
   • Effective against Streptococcus agalactiae

2. Gram-negative bacteria:

   • Covers common urinary tract pathogens, including E. coli and Klebsiella
   • Not effective against Proteus, Pseudomonas, or Serratia

3. Anaerobes:

   • No anaerobic coverage

---

Key Uses:

1. Uncomplicated urinary tract infections (UTIs):

   • Nitrofurantoin is a first-line treatment for acute uncomplicated UTIs, especially in women.
   • It is particularly effective for lower UTIs (bladder infections) due to its high urinary concentration.

2. Prophylaxis:

   • Nitrofurantoin can be used for long-term prophylaxis in patients with recurrent UTIs.

---

Key Notes:

• Not for pyelonephritis: Macrobid should not be used for pyelonephritis (kidney infections) or other systemic infections because it does not achieve therapeutic levels in the bloodstream or kidneys.
• Contraindicated in renal impairment: Avoid use in patients with creatinine clearance <30 mL/min due to inadequate drug concentration in the urine.
• Pulmonary toxicity: Long-term use of nitrofurantoin is associated with pulmonary fibrosis and acute pneumonitis, though these side effects are rare.
• Peripheral neuropathy: Rare but possible, especially in patients with pre-existing conditions such as diabetes or renal impairment.

---

Fosfomycin: Overview

Fosfomycin is another antibiotic used to treat urinary tract infections, particularly those caused by multidrug-resistant bacteria. It has a unique mechanism of action, which makes it useful in cases where other antibiotics fail.

---

Mechanism of Action:

Fosfomycin inhibits bacterial cell wall synthesis by inactivating the enzyme MurA, which is critical for the formation of peptidoglycan, an essential component of the bacterial cell wall.

---

Spectrum:

1. Gram-positive bacteria:

   • Effective against Enterococcus faecalis and Enterococcus faecium (including VRE)
   • Active against Staphylococcus aureus, including MRSA

2. Gram-negative bacteria:

   • Effective against E. coli, Klebsiella pneumoniae, and ESBL-producing Enterobacteriaceae
   • Covers Pseudomonas aeruginosa in some cases, but resistance is more common

3. Anaerobes:

   • No anaerobic coverage

---

Key Uses:

1. Uncomplicated urinary tract infections (UTIs):

   • Fosfomycin is approved for use in uncomplicated UTIs and is especially useful in treating multidrug-resistant pathogens.
   • Typically administered as a single-dose treatment, making it a convenient option for patients.

2. Resistant UTIs:

   • Due to its activity against ESBL-producing and multidrug-resistant bacteria, fosfomycin is often used in patients with resistant UTI pathogens, including some cases of CRE.

---

Key Notes:

• Single-dose treatment: One of the key advantages of fosfomycin is that it can be given as a single 3-gram dose for uncomplicated UTIs, making it convenient for patients.
• Good option for resistant infections: Fosfomycin is particularly useful for UTIs caused by multidrug-resistant organisms like ESBL-producing Enterobacteriaceae and VRE.
• Not suitable for pyelonephritis or systemic infections: Like Nitrofurantoin, fosfomycin should not be used for kidney infections or bloodstream infections, as it achieves poor concentrations outside the urinary tract.
• Resistance can develop quickly: Though useful against resistant organisms, fosfomycin should be used judiciously, as resistance can develop rapidly if overused.

---

Comparison of Macrobid (Nitrofurantoin) and Fosfomycin:

• Macrobid (Nitrofurantoin) is a first-line treatment for uncomplicated UTIs, especially for recurrent or acute bladder infections in women. It requires multiple doses over 5-7 days and is not suitable for systemic infections or patients with severe renal impairment.

• Fosfomycin offers the convenience of single-dose treatment for uncomplicated UTIs, particularly in cases where multidrug-resistant bacteria (e.g., ESBL and VRE) are present. However, it is not appropriate for complicated UTIs or infections outside the urinary tract.

---

Summary:

• Macrobid (Nitrofurantoin) is a first-line antibiotic for uncomplicated UTIs, but it is unsuitable for kidney infections or patients with severe renal impairment. Long-term use can lead to pulmonary toxicity and peripheral neuropathy.
• Fosfomycin is a great option for uncomplicated UTIs, especially in the setting of resistant organisms like ESBL and VRE, and is given as a single dose. However, resistance can develop quickly, and it should not be used for systemic infections or pyelonephritis.

---